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ABSTRACT 
 
Gene therapy vectors are among the treatments currently used to treat malignant tumors. 
Gene therapy vectors use a specific therapeutic transgene that causes death in cancer 
cells. In early attempts at gene therapy, therapeutic transgenes were driven by non-
specific vectors which induced toxicity to normal cells in addition to the cancer cells. 
Recently, novel cancer specific viral vectors have been developed that target cancer cells 
leaving normal cells unharmed. Here we review such cancer specific gene therapy 
systems currently used in the treatment of cancer and discuss the major challenges and 
future directions in this field. 
 
 
INTRODUCTION 
 
CANCER GENE THERAPY – ONCOLYSIS  
Viruses were discovered more than a century ago but from early times diseases like 
cancer and especially leukemia were attempted to be treated with viruses. Throughout the 
recorded history of diseases, there have been observations of cancer regression upon 
natural co-infection with viruses (Sinkovics and Horvath, 1993; Kelly and Russell, 2007). 
During the early twentieth century, based on these observations, several clinical trials 
were conducted via fluid transfer from animal or human bodies that were infected with 
viruses to infect patients with cancer (Hoster et al., 1949). The immune responses of 
those infected patients were most of the times active and so limited efficacy was observed 
but in immune-compromised individuals in many occasions the tumor regressed. 
However, even after obtaining positive results from the tumor shrinkage the morbidity 
from the infection was unacceptable. During those desperate times for science and 
patients, ethical issues were of lower importance, but nowadays those techniques would 
not have met the current ethical standards.  
Initially introduced as a revolutionary biomolecular technology with an unlimited 
potential for curing almost any disease, gene therapy has passed three initial decades of 
turbulence. Its initial concept of using genetic material and introducing it into cell to 
correct defective genes has broadened significantly but in contrast to the large number of 
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clinical trials (more than 1000) that have been conducted or are in process right now, the 
efficacy of gene therapy for cancer therapy has been limited. The lack of alternative 
treatment options in some terminal cancers gave gene therapy the opportunity to prove its 
efficacy and in combination with its lower cost compared to conventional therapies 
sometimes appears as the sole option for some patients. The advances in tissue culture in 
the second half of the twentieth century allowed the production and amplification of 
viruses in a more controlled environment compared to the usage of bodily fluids. Also the 
development of rodent-based models of cancers allowed pre-clinical experimentation 
using a variety of viruses. It was only then when the opportunity to influence the 
development of viruses presented. The possibility to force viruses to grow only in 
specific cancer cells in vitro and subsequently use these viruses in the equivalent human 
tumors was early on utilized, but did not yield in significant advances in virotherapy 
since the tools that were available to improve efficacy, safety and potency were very 
limited.  
Oncolytic virotherapy is a very promising treatment option that uses the replication 
inclination of some viruses in specific cancer cells only. By definition, oncolytic viral 
replication leads to intratumoral viral amplification which ultimately leads to tumor 
destruction with minimal or non-existent damage to nearby non-tumor tissue. Many 
efforts concentrated to the viral tropism and constituted the first generation of oncolytics 
which was based on engineering the virus in such way that genes responsible for its 
replication in normal tissue were removed but were dispensable for the replication in 
tumors (Kaur et al., 2009). Generating viruses that were more specific for cancer cells 
was the ultimate goal since the “lysis” of the infected cell was a native characteristic of 
the virus. It was postulated and later proven that tumor cell environment was more 
suitable than the normal cell environment for viral replication. The latter finding was the 
core of later efforts towards reprogramming viruses to become cancer specific and thus 
safer. These efforts resulted in the first generation of the viruses that has been used 
extensively that utilized the native ability of the virus to enter a lytic cycle and also to be 
targeted to cancer cells specifically using advanced molecular engineering. We are now 
able to visualize the spread of the viruses using reporter genes and evaluate the efficacy 
of each virus in a specific biological system (Doyle et al., 2004; Piwnica-Worms et al., 
2004; Peng et al., 2006; Cattaneo et al., 2008).  
 
VIRAL TROPISM – VIRAL ARMING 
In recent years the demand for specificity for any aspect of cancer therapy to avoid any 
type of toxicity, resulted in the advancement of another approach. Genes that can 
specifically induce a programmed cell death (apoptosis) only in cancer cells but not in 
normal tissue appeared to be very promising approach for cancer therapy since apoptosis 
evasion is a characteristic of cancer cells and the anticancer genes were able to induce it. 
However, significant pitfalls appeared for this approach since the delivery of these genes 
3 
 
was an issue that could not be resolved with the means of delivery that were available. 
Our understanding of cancer has dramatically improved recently and allowed the 
generation of viruses encompassing highly sophisticated molecular characteristics that 
are specific for each cancer type. The first generation of viruses is currently being tested 
in patients for efficacy and concurrently new approaches are being explored for the 
enhancement of their therapeutic potency (Msaouel et al., 2009). Currently clinical and 
pre-clinical studies are testing combination of viruses with pharmacological drugs in 
order to enhance the efficacy of treatment (Alvarez-Breckenridge et al., 2009; Kumar et 
al., 2008). These new studies utilized tumor-specific promoters in order to increase 
efficacy and specificity since the viruses are only able to replicate and lyse specifically in 
a tumor environment. Tumor epitopes are currently being used as targets of newly 
engineered viruses that initiated a revolution in tumor tropism (Hardcastle et al., 2007; 
Waehler et al., 2007). 
A new era for the virotherapy research begun when scientists realized that apart from the 
lytic potential, viruses could be used as gene delivery vehicles. Those viruses were 
named “armed” since they have the ability to lyse the transduced cells and express 
proteins that would enhance the tumor killing efficiency. The genes that are commonly 
arm oncolytic viruses full under four categories: 1) Pro-drug activating enzymes which 
transform a non-toxic chemotherapeutic to an extremely toxic agent which kills tumor 
and non-tumor nearby cells, 2) Reporter genes that are normally used for in vivo 
monitoring of viral distribution, 3) Tumor-microenvironment modulating genes that alter 
significantly the tumor microenvironment so after the lysis of the initial tumor the 
microenvironment would become inappropriate for tumor regrowth and 4) Apoptosis 
inducing genes that can potentially directly enhance the oncolysis by inducing a self- 
suicidal program (Kaur et al., 2009).  
Over the years advances in the field of apoptosis and cell death allowed the identification 
of specific pathways and genes that cancer cells use to escape apoptosis. This book deals 
with the exciting finding that some genes can induce apoptosis specifically in tumors 
cells without affecting nearby or normal tissue (Grimm and Noteborn, 2010). The 
findings are of great importance since specificity is attributed at the gene itself and not in 
the delivery system. One can realize the potential of combining the knowledge of viral 
tropism and specificity with the potency and specificity of the anticancer genes. Arming 
an oncolytic virus that is engineered in a way that can transduce a certain tumor type with 
a tumor specific apoptosis gene is the direction that all the current efforts in the field of 
anticancer genes are focused on.  
 
GENE DELIVERY – VIRAL AND NON-VIRAL SYTEMS  
There are many ways of delivering genetic material to a tissue but in general there are 
two approaches that include viral and non-viral means. Both ways have advantages and 
disadvantages and the majority are developed specifically for a narrow application 
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system. Briefly non-viral gene delivery can be achieved with physical methods which 
include naked DNA, gene gun particle bombardment, electroporation, ultrasound, 
magnetofection and the highly efficient in rodents (so far) hydrodynamic (Nayerossadat 
et al., 2012). Generally while the non-viral physical methods are cost effective and less 
invasive than a viral approach the efficiency of delivery is extremely low and so far there 
only few examples of clinical use of these methods. Most significantly exon skipping 
approaches using oligonucleotides have been used successfully in the clinic for Duchenne 
Muscular Dystrophy (van Deutekom et al., 2007; Kinali et al., 2009; Cirak et al., 2011) 
and antisense oligonucleotides for Spinal Muscular Atrophy are in clinical development 
at present (Passini et al., 2011). Another method of non-viral gene delivery utilizes 
advanced nano-chemistry and nanoparticles that are analyzed extensively in another 
chapter of this book and constitute an attractive approach when compared only with the 
more efficient viral systems. The delivery of the genes for cancer gene therapy is of 
extreme importance since the advances in the anticancer genes identification cannot be 
realized if they cannot be designed into a translational approach for patients. There are 
some key steps that the field has to take in order to improve or perfect the current viral or 
non-viral systems. Targeting and delivery are important determinants of the success of 
cancer gene therapy as is the enhancement of the intracellular delivery, the duration of 
the transgene expression and the local or systemic toxicity. Clinical successes the last 5 
years have breathed new air in the field of gene therapy like i.e. the treatment of X-linked 
SCID, ADA-SCID (Cartier and Aubourg, 2010; Aiuti et al., 2002), X-
adrenoleukodystrophy (Cartier et al., 2009) and Wiskott-Aldrich Syndrome (WAS) 
(Boztug et al., 2010; Aiuti et al., 2013) metachromatic leukodystrophy (Biffi et al., 2013) 
by using ex vivo gene transfer into bone marrow hematopoietic stem cells and autologous 
transplantation or by direct gene transfer in vivo as in the cases of Leber congenital 
amaurosis (Bainbridge et al., 2008; Simonelli et al., 2010) and Parkinson’s disease 
(LeWitt et al., 2011; Palfi et al., 2013) 
 
ONCOLYTIC VIRUSES AND VECTOR SYSTEMS FOR GENE DELIVERY 
There are several virus families and representatives of each family that are currently 
engaged in the battle with cancer. Oncolytic viruses have a native capacity of cell lysis 
and so innate ability of killing. Other viruses do not have the ability of lysing the infected 
cells but have great other characteristics such as transgene capacity and ability to express 
high amounts of the transgene. Viral vectors with backbones from arming-able oncolytics 
or other viruses are of particular interest for this chapter since anticancer genes can be 
used as arming agents for these vectors. Figure 1 shows the oncolytic viruses that are 
currently under clinical trials and viral vectors that are commonly used in gene therapy.  
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Figure 1. Currently ongoing clinical trials utilising oncolytic viral vectors. 
 
Successful delivery systems today include retroviruses, adenoviruses (types 2 and 5), 
adeno-associated viruses (AAV), herpes simplex viruses (HSV), pox viruses, lentiviruses 
and human foamy viruses (HFV). Adenoviruses, AAVs and HSVs have innate oncolytic 
capacity and constitute the most widely used oncolytics. Moreover, the can be efficiently 
armed and used as delivery systems. The engineering of viral vectors include the removal 
of some areas of their genome to manipulate the replication ability, the tropism and 
safety.  
 
VIRAL TROPISM MANIPULATION 
Many types of viruses that contain a high oncolytic potential with low toxicity but with 
no tropism can be manipulated with precise molecular engineering to infect only a tumor 
derived from a specific tissue. Some viruses have natural tropism for a specific cell type 
and this property is extensively used after re-programing the tropism only to cancer cells 
but maintaining the oncolytic efficacy. An example for this class of viruses is the Herpes 
Simplex Virus (HSV) which has natural tropism for neuronal cells but is engineered in a 
way that will only infect neuronal cancer cells but leaving healthy neurons unharmed.  
  
 
6 
 
CANCER SPECIFIC PROTEASES AND ONCOLYTIC ACTIVATION  
Cancer cells have deregulated proteome profile and events of protein overexpression are 
very common. Identification of such proteins that are overexpressed only in cancer cells 
and have minimal or no expression in normal cells has attracted the interest of many 
cancer biologists because each of these proteins could be a potential target for cancer 
therapy. However, virologists effectively used this characteristic of cancer cells in order 
to manipulate viral tropism. They exploited the innate need of viruses to use proteases of 
the host cells in order to be activated and exert any effect in the target cell. In detail, viral 
attachment and activation requires cleavage of viral proteins. Viral proteins contain 
specific sequences that are cleavable by proteases that are ubiquitously expressed in 
cancer cells. Viruses with envelopes such as HIV-1, influenza and paramyxoviruses 
recognize the receptor on a target cell but require the cleavage of their viral glycoproteins 
to allow entry and activation (Klenk and Garten, 1994). Insertion of a cleavage site in the 
virus genome and disruption of the native recognition site for ubiquitously expressed 
peptidase is the strategy that is followed to manipulate viral tropism.  
Among proteins that are highly overexpressed in most types of cancers cells are the 
Matrix Metalloproteinase Proteins (MMPs). They have been associated with high 
metastatic potential, and enhanced cell invasion. Rationale-based therapies targeting 
those proteases with specific inhibitors were developed but with disappointing results due 
to the wide range of substrates and unknown mechanisms of actions of the MMP 
superfamily (Egeblad and Werb, 2002). Additional functions are now attributed to MMPs 
that could explain the failure of MMP inhibitors to provided beneficial outcome for 
cancer patients. However, in cancer gene therapy MMPs’ overexpression is utilized for 
viral tropism reprogramming without the need of pharmacological inhibition. Essentially 
a harmful cancer-cell characteristic is used to destroy the tumor itself. Retroviruses and 
Measles viruses have been recently used in cancer-specific retargeting through the use of 
MMPs (Yi et al., 2011; Cattaneo, 2010). Viral DNA or RNA was manipulated so genes 
that contained protease recognition sequences were disrupted and fused with linkers 
containing sequences that are recognized by MMPs. Surprisingly, the modified viruses 
could only be activated and exert oncolysis preferentially in cells that express MMPs. 
Similar results were obtained from experiments in mice in which modified viruses were 
injected in a background of MMP absence and so no damage (cell death) or infection 
were observed after viral distribution (Morling et al., 1997; Peng et al., 1999; Springfeld 
et al., 2006). Importantly the safety of the viruses was greatly enhanced compared with 
the wild type counterparts through viral tropism re-targeting so the manipulation was at 
the level of particle activation.  
 
CANCER SPECIFIC TRANCRIPTION AND REPLICATION 
Human cancers stem and evolve through mutations on several genes controlling cell 
cycle control, cell death, metabolism, adaptation to extreme environmental conditions, 
7 
 
cessation of the DNA repair machinery or tumor suppressors and oncogenes. A widely 
accepted overview of cancer cells characterizes the hallmarks of cancer that are separated 
in at least six categories (Hanahan and Weinberg, 2011). Manifestation of changes 
occurring by detrimental alterations on cell homeostasis, orchestrates the malignant 
transformation of these cells. Self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of apoptosis, sustained angiogenesis, limitless replication 
potential and tissue invasion and metastasis are the hallmarks of cancer cells (Hanahan 
and Weinberg, 2011). Interestingly, an alignment in the biological dependence of tumor 
cells on those altered pathways was found with viruses. Essentially viruses align their 
replication utilizing pathways of target cells. The recent findings about those similarities 
or dependences of viruses on biological pathways of cancer cells were utilized by 
scientists to alter the viral tropism and manipulate their replication into a cancer specific 
way. Two main approaches have been taken in order to create advanced oncolytic viruses 
with specific tropism. The first approach includes deletion of viral genes that are critical 
for replication of viruses into normal or cancer cells. Essentially specific pathways are 
required for the activation of replication cycle and due to extensive de-regulation of such 
pathways in cancer cells. These attempts to alter the viral tropism using pathway 
dependencies for viral replication have been utilized in the first generation of pre-clinical 
or clinically approved oncolytic viruses like Adenovirus (Ad): ONYX-015, dl922-947, 
Herpes Simplex Virus (HSV): G207, R3616, R1716, bM24-TE, Newcastle Disease Virus 
(NDV), Influenza Virus (IFA), Vesicular Stomatitis Virus (VSV) (Bischoff et al., 1996; 
O'Shea et al., 2004; Heise et al., 2000; Fueyo et al., 2000; Mineta et al., 1995; Cinatl et 
al., 2004; Reichard et al., 1992; Kuroda et al., 2006; Stojdl et al., 2003; Muster et al., 
2004). The second approach for manipulating viral tropism and selective replication is to 
engineer viruses with genes responsible for replication controlled by tumor or tissue 
specific promoters.  
The retinoblastoma tumor suppressor protein (pRB) is significantly altered in many 
human cancers (Sherr, 1996). The same protein is the target of the Conserved Region 2 
(CR2) of the Adenovirus protein E1A. Adenoviruses express early genes that inhibit 
apoptosis and confer limitless replication potential to quiescent cells. Oncolytics based on 
adenoviruses have been carefully manipulated for these genes with advanced molecular 
engineering. Mutations on the E1A genes conferred tumor specificity. Dl922-947 is an 
example of a mutated E1A gene that causes adenoviral based lysis of cells with 
deregulated cell cycle control while other mutants of adenoviruses target specifically the 
pRB pathway that is altered in many cancers.   
After infection, the early gene products of the virus progeny are extremely important for 
the viral replication and oncolysis. Another example for tumor specific replication comes 
from adenoviruses with deleted E1B-55kDa gene. The latter binds to p53 protein and 
induces its degradation, which essentially leads to apoptosis inhibition that would allow 
viral replication. Deletion of E1B would allow the virus to enter the cell but since there is 
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no inhibitory effect on p53 since E1B is deleted, the p53 will induce apoptosis and kill 
the target cell not allowing viral replication. In that scenario tumor specific replication is 
achieved using those specific oncolytics in tumors with defective p53 pathway that is a 
very common genetic abnormality in a wide range of human cancers. The idea was 
ingenious and the first oncolytic to utilize that strategy was ONYX-015 (Bischoff et al., 
1996). However, such simple rational biology was not able to generate what was thought 
to be a tumor specific replication-able oncolytic. It was noted later that the biology of 
viruses is more complex than initially anticipated and ONYX-015 could also replicate in 
cells with wild type p53 (Harada and Berk, 1999; O'Shea et al., 2004; Dix et al., 2000). 
As findings in tumor biology advance, so does the utilization of tumor defects for 
selective replication of the viruses. Defective interferon response pathway that is 
normally responsible to initiate apoptosis due to viral infection is commonly attenuated in 
cancer. Extensive activation of Ras/Raf1/MEK/ERK pathway is also another common 
genetic abnormality. VSV or NDV oncolytics are usually sensitive to interferon 
cytokines. However due to the attenuation of this antiviral response in host cells the 
viruses are able to replicate selectively in tumors (Stojdl et al., 2003; Noser et al., 2007; 
Lorence et al., 1988; Reichard et al., 1992). Activation of the Ras/MEK pathway in 
human cancers results in the inhibition of the protein kinase R (PKR) pathway. The latter 
is a host defense pathway, which halts protein synthesis of virally-infected cells and 
induces their death. Since activated Ras leads to inactivation of PKR, oncolytics like 
HSV-1 or Influenza virus A (IFA) are able to conditionally replicate only in cancer cells 
using this common defect of protein synthesis inhibition in tumors (Smith et al., 2006; 
Veerapong et al., 2007; Bergmann et al., 2001; Muster et al., 2004). Ras pathway has a 
central role in tumor initiation, progression and sensitivity to treatment. Being so central 
in the biological processes that govern tumor cells makes it prone to activation by many 
different signals stemming from upstream tyrosine kinase receptors or regulatory 
oncoproteins. Examples of such proteins that potently activate Ras are the Epidermal 
Growth Factor Receptor (EGFR), or BRAF or many other tyrosine kinases that require 
Ras activation to signal downstream. In that context Ras can potentially have additional 
abilities that are utilized by oncolytics for conditional replication in tumors.  
Cancer specific replication is a central component of oncolytic virotherapy. Although is a 
major field of research constitutes an autonomous level for improving viral safety and 
specificity. This chapter is aiming to determine the methods for tumor specific 
destruction that can be integrated into a new generation of viruses that would have 
several levels of controls from virus targeting, replication and induction of apoptosis. The 
latter is essential  
 
CANCER SPECIFIC PROMOTERS 
The generation of disease models through transgenic animals was made possible by the 
identification and use of tissue or organ specific promoters. Specificity of protein 
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expression allows controlling of toxicity and off target effects to non-target cells. The 
ability to direct the level of gene expression at a specific site was utilized by virologists in 
order to generate oncolytics that contained genes responsible for viral replication under 
the control of a tissue specific promoter. Although the approach could not be applied to 
all the available oncolytic viruses due to restrictions in their biology (i.e. RNA viruses), it 
could potentially lead to effective agents for directed oncolysis. There are two ways for 
utilizing promoter specific expression of viral genes. The first is to use promoter 
sequences from genes that are tumor specific. A representative example of such 
promoters is the hTERT gene promoter (Huang et al., 2003). Human Telomerase Reverse 
Transcriptase promoter is highly expressed in tumors with minimal or no expression in 
normal tissues. The high tumors expression makes it an attractive tool for cancer specific 
replication of viral genes. An alternative method of using a promoter to confer replication 
specificity is to use tissue-specific promoters. Characteristic examples of such cases are 
the PSA (prostate specific antigen) gene promoter for prostate cancers replication the 
tyrosinase gene promoter for skin cancers or alpha-fetoprotein for liver cancers (Everts 
and van der Poel, 2005). Although the second approach is rationale-driven and could 
potentially revolutionize tumor selective replication of viruses, the strength of each 
promoter system needs to be investigated extensively since a weak promoter would 
probably diminish the oncolytic potential of a virus. In turn combinatorial approaches 
could be employed in order to achieve high specificity and increased potency (Nagano et 
al., 2005). 
 
VIRAL BINDING THROUGH TUMOR-SPECIFIC RECEPTORS 
The binding and the entry of an oncolytic virus onto and into a cancer cell is a pivotal 
step for successful tumor destruction. There are many factors that can determine the 
specificity of each oncolytic to bind to a specific receptor and the complexity that 
governs the specificity of binding determines the feasibility of molecular engineering of 
recombinant viruses to target cancer-specific receptors. Adenoviruses enters the cells 
through endocytosis (Meier and Greber, 2003) after the binding of the fiber knob of the 
proteins on the viral capsid to the Coxsackie-Adenovirus-Receptor (CAR) on the cell 
surface. Subsequently it gets internalized through clathrin pits via interaction of integrins 
on the host cell with the RGD motif on the virus (Hardcastle et al., 2007). HSV based 
oncolytics use a different set of receptors (Spear, 2004) for viral entry. The tumor 
necrosis factor family members, proteoglycans and nectin-1 (Gianni et al., 2004) as well 
as nectin-2 are the host-cell surface receptors that are preferred by HSV without being the 
only ones. Multiple ligands are also available on the surface of the HSV like 
glycoproteins gB, gC or gD. In contrast to adenoviruses, HSVs are enveloped viruses 
which adds an additional step to the entry of the virus into the host cell or another level of 
complexity. Endocytosis like the adenovirus or fusion with the plasma membrane are the 
two different routes required for viral entry. However, the choice of the route that the 
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infection is going to follow is not determined by the receptor rather on which cells this 
receptor is expressed on. Some viruses such as vaccinia have a very broad spectrum of 
cells that could infect and so far there are no exclusive receptors that these viruses utilize 
for viral entry (Guo and Bartlett, 2004). CCR5 receptor has been recently shown to allow 
viral entry to previously not permissive cells but there is limited specificity by this family 
of viruses in comparison to adenoviruses or HSVs.  
The hypothesis is that if the viruses are engineered in a way that can express ligands for 
specific receptors on the host cell membrane that would allow specific entry to the cell of 
interest. Researchers are now utilizing bispecific ligands (bind both the receptor on the 
host cell and receptors on the virus) that are expressed through engineered adenoviruses 
in order to allow entry through a cancer cell receptor. Likewise there have been attempts 
to specifically target HSV to EGFR expressing cancer cells through a gD-specific 
bridging molecule (Nakano et al., 2005) however since HSVs require an additional step 
namely fusion with the plasma membrane or endocytosis, efforts are now shifted to the 
separation of those two events in order to generate a more specific strategy for viral entry.   
Latest advancements in receptor targeting report the use of domains that present 
antibody-like characteristics and specificity. However, antibodies are extremely difficult 
to be engineered in to viral proteins due to their size and their tetrameric form. Also the 
contain disulphide bonds which increases the complexity and makes it extremely difficult 
to be utilized for vector retargeting. In order to fill this gap in this technical conundrum 
single-chain Fragment variables (scFv) were developed which contain the variable region 
of the heavy and light chains. Proof of principle was obtained using enveloped viruses 
such as the Measles Virus (MV) for CD20 binding in Hodgkin’s lymphoma (Bucheit et 
al., 2003) or CD38 in myeloma (Peng et al., 2003). HSVs were also engineered to 
express scFvs as well as in other enveloped viruses that are generally easier to be 
genetically manipulated.  
 
VIRAL VECTORS FOR TRANSGENE DELIVERY  
There are multiple RNA and DNA viruses that have been or are being used in cancer 
gene therapy. However, several of them are being used as tools for gene therapy in other 
diseases like neurodegenerative diseases or diseases with known gene defects. As it was 
previously mentioned in this chapter Figure 1 shows a virus classification according to 
their fundamental characteristics. Below the main classes of viruses that are used as a 
gene delivery methods are described. Anticancer gene transfer can be utilized with any of 
the vectors described below but with some restrictions in size of the cancer specific 
apoptosis genes. Since apoptosis is induced in a tumor-cell-specific manner vectors with 
low oncolytic activity can also be used. Arming oncolytics with cancer-specific apoptosis 
genes might prove a better approach combining all the levels of specificity that we 
described above with the potency of an apoptosis-inducing gene.  
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ADENOVIRUSES 
More than 100 types of adenoviral serotypes have been described so far and have been 
derived from a wide range of species. Types 2 or 5 are common adenoviruses that most 
humans have been exposed to. Although natural infection by an adenovirus or gene 
therapy application would probably be acute and limited adenoviruses have been used in 
gene therapy applications mostly due to their capacity for gene of interest (~36kb), 
because of the high expression level of the transgene and because of their safety profile 
(Vorburger and Hunt, 2002). Adenoviruses do not integrate into the host’s genome and 
can transduce dividing and non-dividing cells. Having all these advantageous attributes, 
adenoviruses became one of the most widely used vectors for cancer gene therapy 
(Thomas et al., 2003). Although superior in many characteristics than other vectors, 
adenoviruses initiate a rapid and strong immune response, which limits the level of 
transgene expression while being completely eliminated from the host cells (Green and 
Seymour, 2002). Strong immunogenic response might benefit tumor destruction but is at 
the same time extremely dangerous for the patient (Wu et al., 2001). A common 
drawback for using adenoviruses as gene therapy vectors is the availability of CAR 
which varies in expression on the membrane of cancer cells (Bergelson et al., 1997). In 
that sense efforts have been focused on the reduction of the immunogenic response by 
removing nearly the complete viral genome coding sequences. The latter acquired the 
name “gutless adenovirus” and requires the help of a helper virus in order to produce 
viral particles (Koehler et al., 2005; Koehler et al., 2006). Although deficient in the 
ability of replication as standalone vector, it maintains high infectivity rates and wide 
tropism. This new generation of adenovirus has been tested in preclinical and clinical 
models of cancer with promising results but the toxicity of the helper virus remains too 
high and at a level that is not acceptable for use in human clinical trials. There are many 
examples of use of adenoviruses for cancer gene therapy mainly serotypes 2 and 5 which 
were engineered (“armed”) to express suicidal genes, tumor suppressors, immune 
boosters, oncogenic inhibitors, antigens for tumor vaccines, antiangiogenic factors, 
prodrug activating genes and many others. Further details will be discussed later about 
“armed” oncolytics.  
 
ADENO-ASSOCIATED VECTORS (AAVs) 
As their name imply, AAVs are similar to adenoviruses in many extends, however, they 
contain a few but fundamental differences which differentiate them from the common 
adenoviruses. They have a deficiency in replication and pathogenicity that enhances their 
safety profile and show superiority against adenoviral vectors (Lai et al., 2002). 
Moreover, AAV infection in humans does not associate with any diseases or specific 
immunogenic responses. Another fundamental difference but in favor of the adenoviruses 
this time, is the capacity of AAVs. Gene inserts bigger than 4.8kb cannot be inserted into 
an AAV vector. Examples of successful use for AAVs in the clinic include hemophilia B, 
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Leber congenital amaurosis, PD and alpha-1 antitrypsin deficiency (Flotte et al., 1996; 
Kay et al., 2000; Bainbridge et al., 2008; Simonelli et al., 2010). The use of AAVs was 
extended to cancer with many successful pre-clinical models of many types of cancers 
using AAV vectors and recently an AAV vector expressing the anticancer genes IL-24 
and apoptin was used in a pre-clinical model of hepatocellular carcinoma (Yuan et al., 
2013). AAV vestors are currently under pre-clinical development for use in clinical trials 
while oncolytic Adeno-associated viruses currying the CEA gene are currently being 
tested for efficacy and safety in stage IV gastric cancer (www.clinicaltrials.gov).  
 
HERPES SIMPLEX VIRUSES  
Herpes simplex virus can cause severe lethal encephalitis and it occurs naturally as a 
pathogen as an enveloped virus. HSV has been extensively used as a viral vector for 
virotherapy as an oncolytic or as a carrier vector to induce cytotoxic effects. HSV-1 in 
comparison with other viral vectors especially compared to adenoviral vectors have 
superior characteristics for cancer virotherapy (Todo, 2008b). It contains a large genome 
that allows deletion of non-essential genes and insertion of therapeutic genes of interest 
(153kb is the genome while around 30kb can be entirely deleted). Only minimal 
infectious virions are needed for a large scale and effective cell killing since it is 
exceptionally cytolytic. HSV is not an integrating virus so it does not affect the host 
genome stability and it has itself a very stable DNA genome. It can infect most tumor 
types and has been extensively investigated in neuronal cells which are normally difficult 
to transduce and so brain tumor therapy can prove specifically effective using HSV 
(Todo, 2008a; Mineta et al., 1995). In case of adverse effects in a patient, there are many 
available anti-virals for HSV that can prevent or calm negative effects of infection.  
HSV delivery systems include the DISC system that is name as such from Disable 
Infectious Single Copy virus. DISC viruses contain a mutant glycoprotein H and are 
replication defective (Trobridge, 2009). HSV-G207 was the first HSV-1 based virus that 
was used in a clinical trial in the United States (Markert et al., 2000) and the results have 
proved the efficacy and potency of the virus. So far the third generation of HSV 
oncolytics is being developed to improve specificity, tropism and safety. To accomplish 
that scientists are identifying non-essential genes and delete (alpha47 gene – to create the 
HSV-G47delta 3
rd
 generation) (Chou et al., 1990; Todo et al., 2001) them in order to 
induce further an immune response to attack the tumor and better cytotoxic effects 
(Nayerossadat et al., 2012).  
Epstein-Bar viruses (EBVs) are a class of herpes viruses that retain some of the attractive 
characteristics of the HSVs. EBVs can accommodate large DNA fragments and when 
inserted into the nucleus they stay as circular episomes allowing long term, non-invasive 
gene expression. EBVs have natural tropism for B-cells and have been used before to 
treat B-cell lymphoma and immunotherapy for cancer. 
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POX VIRUSES 
Vectors derived from poxviruses are used for extremely high cytoplasmic expression of 
the engineered transgene. The capacity of that vector is relatively big being able to 
accommodate fragments of 25kb. The high expression and the high capacity are the two 
major characteristics of the poxviridae family vectors (Moroziewicz and Kaufman, 2005). 
Gene delivery with Poxviruses has not advanced so far as expected. The complexity of 
the viruses and the complicated molecular engineering that is required to achieve cloning, 
production and expression presents as a major barrier for the advancement of this vector 
as an effective gene delivery option (Gomez et al., 2008; Moss, 1996). For transgene 
insertion a step of homologous recombination or in vitro ligation is required in order to 
produce recombinant vaccinia virus (Moss, 1996). There have been some successful 
attempts to use poxviruses in cancer gene therapy and especially in breast, prostate, 
colorectal and lung cancer. 
 
RETROVIRUSES-LENTIVIRUSES  
Transduction of dividing cells and stable integration of the virus into the host genome are 
the main characteristics of retroviruses. They are one of the most frequently used delivery 
vectors for somatic or germline gene therapies. Retroviruses can pass through the nuclear 
pores of mitotic cells and so they are ideal for in situ treatment. The capacity of 
retroviruses is relatively restricted (~8kb) after the removal of all the viral genes. They 
have been used as gene therapy options of X-SCID with great success but with a major 
fatal disadvantage. They specifically integrated upstream of the lymphoproliferative 
LMO2 gene and activated this gene so leukemia was the clinical outcome in some 
patients. This has now been bypassed by use of SIN LTRs or by using lentiviral vectors. 
Familiar hyperlipidemia was another example of use for the retroviruses however their 
uses remain extremely restricted in the clinic. Their ability to integrate into the host 
genome raises safety issues since they can potentially inactivate tumor suppressors or 
cause oncogene activation.  
Lentiviruses are a subclass of retroviruses. They possess the characteristic of the 
integration into the host genome but they have the superior ability to transduce non-
dividing cells making them ideal for gene therapy of neurological diseases. They can 
accommodate transgenes up to 8kb and can transduce a large number of cells without 
immunological responses or toxic side effects. Their natural tropism is for neuronal stem 
cells and they have been extensively used for ex vivo gene delivery in the central nervous 
system. The integrated transgenes are stably expressed for long periods without having 
any immunogenicity. Successful use of these vectors has been achieved in PD, 
metachromatic leukodystrophy, X-Adrenoleukodysrtophy and several 
immunodefienciencies (WAS, ADA-X SCID). Lentiviruses have also been used for 
cancer immunotherapy (through enhancement of dendritic cell antigen presentation) of T-
cell leukemia or prostate cancer when bound to trastuzumab (Stripecke et al., 2003; 
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Zhang et al., 2009a).  
 
ARMING VIRUSES FOR CYTOTOXIC VIROTHERAPY 
Per definition, cancer, is the irregular and unrestrained proliferation and multiplication of 
cells that are able to invade adjacent tissues and are able to metastasize to proxy regions 
of the body through the bloodstream (Vogelstein and Kinzler, 2004). While 
chemotherapy and cytotoxic therapy has brought tremendous progress to cancer 
therapeutics it presents with detrimental side effects that hamper the benefits of the tumor 
shrinkage or destruction. Common practice so far has been the systemic administration of 
cytotoxic therapies that instead of affecting the tumor specifically they affect all the 
human tissues non-specifically and uncontrollably (Meirow and Nugent, 2001). A new 
era for cancer therapeutics has emerged through the use of targeted and rationale-based 
therapies using small molecular inhibitors of proteins or pathways that are specifically 
deregulated in certain cancers. Such examples are the use of tyrosine kinase inhibitors for 
Epidermal Growth Factor Receptor (EGFR) mutations or amplifications, for Anaplastic 
lymphoma kinase (ALK) and many other common genetic alterations in cancers. 
Although initially effective these therapies are not long-lasting since resistance almost 
always occurs and tumors re-grow and they require more effective treatments like 
chemotherapy or radiation (Schliemann and Neri, 2007; Friedrich et al., 2004; Ansari et 
al., 2009; Sasaki et al., 2010). Distinguished among these research endeavors is the 
concept of oncolytic virotherapy that utilizes wild-type or recombinant viruses to 
selectively infect and kill cancer cells while leaving normal tissues viable or not affected. 
There has been an era of rapid development of oncolytics that changed the way we 
thought of cancer therapy. Specificity and effectiveness are the main challenges that 
scientists face in order to generate new recombinant viruses but tremendous progress has 
been achieved through the strategies that were discussed before for viral tropism and 
specificity. In addition to targeting, strategies are often employed to amplify the cytolytic 
capabilities of oncolytic viruses to increase their efficacy. This process was named 
“oncolytic arming” since a transgene is helping the innate cytotoxic ability of a virus 
(Cattaneo et al., 2008). Arming of a virus requires a careful selection of a viral vector that 
will be used as oncolytic agent and can be achieved through three major strategies that 
are discussed below and are: pro-drug oncolytic arming, pro-apoptotic gene arming and 
microenvironment-regulation-able gene arming.  
 
PRO-DRUG ARMING  
Expression of so-called prodrug convertases by the virus is an approach where an non-
harmful enzyme is engineered to be expressed as the oncolytic infects specifically the 
cancer cell. Subsequently, systemic delivery of a pro-drug follows and in cancer cells that 
are infected with the oncolytic expressing the enzyme, a chain reaction of cell suicide is 
initiated. This strategy is named gene-directed pro-drug activation therapy and has many 
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examples where it was used with very promising results. One characteristic class of pro-
drug arming is the expression of the thymidine kinase gene in HSV vector that is able to 
monophosphorylate ganciclovir, which in turn is converted to triphosphorylated forms 
that induce cell death by blocking DNA synthesis (Boviatsis et al., 1994; Chase et al., 
1998). Several other systems have been described such as the nitroreductase in 
combination with the pro-drug CB1954 or the cytosine deaminase (CD) with the pro-drug 
5-fluorocytosine, which is forming the chemotherapeutic 5-fluorouracil (5-FU) 
(Chalikonda et al., 2008; Foloppe et al., 2008). Moreover, fusion of two different 
enzymes has been employed for increased killing efficacy, in difficult to target cancers. 
The majority of the viruses that have been used to deliver these genes were non-
replicative but recently replication-able oncolytics have been employed for pro-drug 
suicidal strategy (Wong et al., 2010). 
 
MICROENVIRONMENT GENE MANIPULATION ARMING 
The microenvironment of tumors is a very complex intercommunicating cell network that 
supports the solid tumor for its growth and expansion. It consists of host fibroblasts, 
immune cells, endothelial cells, immune cells and pericyte cells. The tumor is supported 
by a vast amount of signals that constitute the extracellular matrix (ECM), which 
dominantly controls tumor vascularization, tumor growth and expansion, invasion and 
metastasis. The network of signals is a complicated network of secreted proteins that 
provide structural support for the tumor and its stroma but also is a biological barrier that 
prevents administration of therapies to the tumor core. The barrier is not only effective 
against chemical therapeutics. It is preventing the host’s immune cells to attack the tumor 
protecting it from the most clever and efficacious defense system in nature (immune 
system). Therefore, the need for agents that would manipulate the tumor 
microenvironment and convert it to a more permissive barrier became imperative. To this 
end oncolytics armed with genes that can modify or destroy the tumor microenvironment 
were generated. The viruses that were employed to carry the microenvironment 
disseminating genes were armed with anti-angiogenic factors, with chemokine/cytokine 
that mediate tumor microenvironment or proteases or glycosidases that have a direct 
effect on stroma stability and structure. Adenoviruses or HSV were armed with 
inactivating Vascular Endothelial Growth Factor Ligands (VEGF) which stopped the 
intracellular signaling and reduced the rate of angiogenesis (reviewed in Kaur et al., 
2009). Inhibitors of matrix metalloproteinases also achieved modification of angiogenesis 
where oncolytics carrying the gene Tissue Inhibitor of Metalloproteinase 3, was 
expressed (Spurbeck et al., 2003; Ahonen et al., 2002; Lamfers et al., 2005; Mahller et 
al., 2008). Numerous examples of viruses armed with anti-angiogenic peptides, with 
shRNAs that downregulate fibroblast growth factor receptor (FGFR) signaling, 
antibodies that would affect interleukin 8 signaling were used with satisfactory results in 
preclinical and clinical models of many cancers. The network of the proteins that 
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comprise the tumor microenvironment is so complicated that requires extensive 
knowledge of the signaling networks that are activated due to their expression. The main 
approach is to identify a way to disseminate the tumor microenvironment and allow the 
immune system or the oncolytic virus to attack the tumor. For a detailed and a 
comprehensive review about the tumor microenvironment modulating oncolysis please 
refer to the work of Chiocca and colleagues (Kaur et al., 2009).   
 
PRO-APOPTOTIC GENES ARMING  
One of the cancer hallmarks, as discussed in a previous paragraph, is the inhibition of 
programmed cell death (apoptosis) whereby tumor cells are unable to commit to their 
innate suicidal program even in the presence of extensive deregulation of their 
homeostasis. Research in the apoptosis field has revealed a well-defined network of 
genes that can induce apoptosis and are inactivated in cancer or genes that can inhibit 
apoptosis and they are aberrantly expressed in human malignancies. Viral vectors as 
powerful delivery systems were employed to deliver pro-apototic genes or gene such as 
tumor suppressors that can deploy the apoptotic response. An early example of the use of 
viral vectors to deliver pro-apoptotic genes in cancer gene therapy was the use of an 
adenoviral vector for the expression of the TP53 gene. The China State Drug and Food 
Administration approved this vector (Gendicine) for the treatment of head and neck 
cancer but its efficacy was limited due to the non-replicative phenotype (E1A gene 
deletion) (Peng, 2005). On the other hand oncolytics, which are replication-competent 
appear as more effective delivery systems especially when armed with apoptosis-
inducing genes. One example of an effective oncolytic armed with a tumor suppressor is 
the generation of an oncolytic adenovirus with E1A under the hTERT and hypoxia 
response element promoter and the TP53 gene under a cytomegalovirus promoter. This 
virus combined tumor selectivity, p53 tumor suppressor expression and oncolysis (Wang 
et al., 2008). Cancer is a multifactorial disease and many signaling pathways are altered 
during its initiation and progression. An effective strategy would target pathways and 
avoid single genes in order to induce the apoptosis cascade (Jones et al., 2008). A good 
example of such approach is the use of TNF-Related Apoptosis-Inducing Ligand  
(TRAIL). TRAIL oncolytic gene therapy utilized the chimeric Adenovirus AD5/35 which 
is able to transduce cancer cells without the use of a receptor, replicate in cancer cells and 
allow TRAIL expression which lead to apoptosis induction (Chen et al., 2009). Efficacy 
of this vector was shown in leukemia, gastric cancer and pancreatic cancer in vivo (Zhang 
et al., 2009b, Jin et al., 2009). TRAIL has been extensively analyzed in a previous 
chapter of this book since it is one of the “anticancer genes” which are able to promote 
tumor-specific apoptosis initiation when overexpressed without being toxic in normal 
cells. MDA7 or NOXA also utilized an adenoviral delivery system to be delivered 
intratumorally and induced apoptosis in xenograft models of cancers (Suzuki et al., 2009; 
Sauane et al., 2008). The use of adenoviruses to deliver anticancer genes is based on an 
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obvious scientific rationale. Adenoviruses (as described before) are able to stay as 
episomes around the host DNA and drive really high expression of the gene of interest. 
This is particularly important since anticancer genes are able to induce their tumor-killing 
effects only when they are overexpressed and the level of expression correlates with the 
apoptotic phenotype. However, extremely high expression of apoptotic gene can impede 
the advantageous effects of a combinatorial strategy with oncolytics. Premature apoptosis 
in the infected cells can reduce the virus progeny yields and counteract the oncolytic 
activity of the virus. An efficacious approach would be to induce apoptosis in a delayed 
manner in order to allow viral replication, apoptosis induction and lysis of the cells. The 
principle of these types of genes is that they can be overexpressed but their effect on cell 
viability is only exerted in cancer cells and not normal cells due to extensive deregulation 
of pathways that control these genes in human cancers. Most of the “anticancer genes” 
have been used to arm viruses and have proven their efficacy both in vitro and in vivo. 
Some of them (HAMLET, TRAIL or MDA7) entered or are entering clinical trials 
(Hallgren et al., 2008; Inoue et al., 2006; Tong et al., 2005; Fox et al., 2010). A novel 
approach using the unique characteristics of oncolytic viruses and tumor-specific 
apoptosis genes can open a new window in cancer therapeutics since the use of anticancer 
genes introduce an additional step in specificity and efficacy. 
 
HURDLES FOR THE USE OF VIRUSES AS DELIVERY VECTORS 
While oncolytic virotherapy has emerged rapidly as a treatment option and distinguished 
itself from cytotoxic therapies, it has not yet reached its full potential due to several 
limitations or further research that is needed in certain areas. As discussed earlier in this 
chapter the level of expression of each gene plays an important role for the determination 
of the therapeutic window. There is an urgent need for the regulation of transgene 
expression which can be achieved either with the use of specific promoters or with the 
utilization of regulatory elements that can be controlled exogenously through systemic 
drug administration (Goverdhana et al., 2005). The expression of the transgene can be 
coupled with advance in vivo monitoring of expression levels in order to be able to detect 
signaling pathway alteration after viral administration and in combination with a 
controllable expression system to manipulate the course of the tumor progression 
(Winkeler et al., 2007).  
There is currently an emerging field of research that is focusing on the use of carrier cells 
for viral delivery to tumor sites. The reason that this approach is particularly significant is 
the possibility of pre-existing immunity (Guo et al., 2008). The idea stems from the fact 
that certain cell types have natural tropism for tumor cells so in principle a cell infected 
with an oncolytic ex vivo can be injected in order to reach the tumor site and so the 
oncolytic will lyse this cell and infect the main tumor site. Circumventing pre-existing 
immunity is a major hurdle that oncolytic virotherapy faces. The majority of human 
population has previously been exposed to viruses that are used as oncolytics and so the 
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administration of a viral population will be effective only in one round of injection (Guo 
et al., 2008). Part of the immune response that is initiated after viral infection is the 
complement activation. Some viruses like the vaccinia or the HSV produce specific 
proteins that can neutralize the complement activation (Ferguson et al., 2012). However, 
almost certainly a viral infection will lead to an immune reaction that needs to be 
suppressed or bypassed for effective oncolytic virotherapy. The process of protecting the 
viruses from pre-existing immunity or acute immune response is called viral shielding 
and has the same principle as the “Trojan horse”. Briefly, the immune system is by 
passed by viruses that are camouflaged under a different capsid or shielded with chemical 
compounds like polyethylene glycol in order to “trick” the immune system and be deliver 
to the tumor site. Stem cells, cancer stem cells, endothelial cells and progenitors, immune 
cells and even cancer cells as carriers have been, or are being tested for their efficacy and 
proof of principle (Iguchi et al., 2012; Hamada et al., 2007; Stoff-Khalili et al., 2007). 
Another approach to overcome the pre-existing immunity is the temporal 
immunosuppression using pharmacologic interference to bypass the adaptive and innate 
immune response. The latter would allow opening of the therapeutic window till the virus 
reach the tumor site and start the destruction of tumor cells.  
Another obstacle for effective oncolytic virotherapy is the unspecific uptake of the virus 
by some organs or tissues like lungs, blood or spleen. Vaccinia or adenoviral vectors have 
been extensively studied for identifying ways to reduce viral uptake by the organs. These 
ways include pharmacological inhibition of virus-organ interaction or molecular ways by 
mutating molecules on the surface of the virus to prevent crosstalk with unspecific tissue 
(Ferguson et al., 2012).  
While scientists have taken large steps in understanding the viral biology there are 
significant gaps in the mosaic of viridae family. One of the major limitations that 
scientists face is the partial or incomplete knowledge of viruses and that became apparent 
with the use of ONYX-015 which was found that it can replicate in cells that also had 
wild type p53 protein. Furthermore, understanding the viral biology is only part of the 
story. Our detailed knowledge should also be applied to the cancer itself. Current 
comprehensive approaches to characterize the genetic profile of all the tumors (i.e. The 
Cancer Genome Atlas-TCGA) provide invaluable information about the molecular basis 
of each cancer. This information can be used in order to generate new strategies that 
target several other molecular pathways that are affected in the tumor milieu. 
 
CONCLUSIONS-FUTURE OF THE FIELD  
Oncolytic virotherapy with viruses armed with anticancer genes is inevitably going to be 
a new big player in the field of virotherapy. The ultimate goal for each medical filed is to 
be able to apply the scientific finding and the years of research in pre-clinical and clinical 
models to human patients. To achieve that, three major milestones need to be 
accomplished: increased safety, enhanced efficiency and improved knowledge of the 
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tumors. Infectious agents as are the viruses need to be carefully handled and primarily 
tightly controlled since apart from only being cleverly engineered to be immunoinvasive 
for the tumors they have to be carefully control to protect the patient and the patient 
environment. Arming oncolytics should be the future directions of the field. Above 
discussed are the advantages of oncolytic arming. However, careful consideration should 
be given to the choice of transgenes that will be used for arming. Pro-apoptotic genes that 
have no other control features are obviously dangerous and unacceptable. Fortunately, 
oncolytics have their own control systems as they were discussed in previous paragraphs 
so arming them with genes that when overexpressed can induce apoptosis only in cancer 
cells can be a clever strategy to move forward. A fundamental paradigm of cancer 
treatment is that there is no unique and stand-alone therapeutic regiment that will cure 
cancer. The aforementioned relative de-motivating statement stems from the fact that is 
from its nature a multifactorial disease. Combinatorial approaches that have already been 
taken proved more efficient that mono-therapies and when oncolytics where combined 
with cytotoxic therapies the disease progression was the majority of the times improved. 
Cancer therapeutics were recently improved by the utilization of rationale-based therapies 
using small molecule inhibitors targeted against specific molecular pathways that are 
deregulated in cancer cells (Aggarwal, 2010). Non-small cell lung adenocarcinomas are 
great examples of a lung cancer types that have benefited from the use of targeted 
therapies with unprecedented initial responses and limited side effects (Pal et al., 2010). 
However, acquired resistance to the drug almost always occurs, so oncolytics armed with 
anticancer genes should be utilized to enhance the effects of small molecule inhibitors 
and to prevent development of drug resistance which will ultimately lead to disease 
improvement and amended clinical outcome. Research is already directed towards the use 
of combinatorial approaches of targeted therapies and oncolytics as clinical successes in 
melanoma and glioblastoma multiforme (Msaouel et al., 2013; Clarke et al., 2010; 
Donnelly et al., 2012; Natarajan et al., 2011) denote. We are entering an era where we 
possess the tools, we are able to use new technologies and the time has come to use them 
in our favor. 
 
Bibliography 
AGGARWAL, S. 2010. Targeted cancer therapies. Nat Rev Drug Discov, 9, 427-8. 
AHONEN, M., ALA-AHO, R., BAKER, A. H., GEORGE, S. J., GRENMAN, R., 
SAARIALHO-KERE, U. & KAHARI, V. M. 2002. Antitumor activity and 
bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. 
Mol Ther, 5, 705-15. 
AIUTI, A., BIASCO, L., SCARAMUZZA, S., FERRUA, F., CICALESE, M. P., 
BARICORDI, C., DIONISIO, F., CALABRIA, A., GIANNELLI, S., 
CASTIELLO, M. C., BOSTICARDO, M., EVANGELIO, C., ASSANELLI, A., 
CASIRAGHI, M., DI NUNZIO, S., CALLEGARO, L., BENATI, C., RIZZARDI, 
20 
 
P., PELLIN, D., DI SERIO, C., SCHMIDT, M., VON KALLE, C., GARDNER, 
J., MEHTA, N., NEDUVA, V., DOW, D. J., GALY, A., MINIERO, R., 
FINOCCHI, A., METIN, A., BANERJEE, P. P., ORANGE, J. S., GALIMBERTI, 
S., VALSECCHI, M. G., BIFFI, A., MONTINI, E., VILLA, A., CICERI, F., 
RONCAROLO, M. G. & NALDINI, L. 2013. Lentiviral hematopoietic stem cell 
gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151. 
AIUTI, A., SLAVIN, S., AKER, M., FICARA, F., DEOLA, S., MORTELLARO, A., 
MORECKI, S., ANDOLFI, G., TABUCCHI, A., CARLUCCI, F., MARINELLO, 
E., CATTANEO, F., VAI, S., SERVIDA, P., MINIERO, R., RONCAROLO, M. 
G. & BORDIGNON, C. 2002. Correction of ADA-SCID by stem cell gene 
therapy combined with nonmyeloablative conditioning. Science, 296, 2410-3. 
ALVAREZ-BRECKENRIDGE, C., KAUR, B. & CHIOCCA, E. A. 2009. Pharmacologic 
and chemical adjuvants in tumor virotherapy. Chem Rev, 109, 3125-40. 
ANSARI, J., PALMER, D. H., REA, D. W. & HUSSAIN, S. A. 2009. Role of tyrosine 
kinase inhibitors in lung cancer. Anticancer Agents Med Chem, 9, 569-75. 
BAINBRIDGE, J.W., SMITH, A.J., BARKER, S.S., ROBBIE, S., HENDERSON, R, 
BALAGGAN, K., VISWANATHAN, A., HOLDER, G.E., STOCKMAN, A., 
TYLER, N., PETERSEN-JONES, S., BHATTACHARYA, S.S., THRASHER, 
A.J., FITZKE, F.W., CARTER, B.J., RUBIN, G.S., MOORE, A.T., ALI, R.R. 
2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N 
Engl J Med., 358(21), 2231-9. 
BERGELSON, J. M., CUNNINGHAM, J. A., DROGUETT, G., KURT-JONES, E. A., 
KRITHIVAS, A., HONG, J. S., HORWITZ, M. S., CROWELL, R. L. & 
FINBERG, R. W. 1997. Isolation of a common receptor for Coxsackie B viruses 
and adenoviruses 2 and 5. Science, 275, 1320-3. 
BERGMANN, M., ROMIRER, I., SACHET, M., FLEISCHHACKER, R., GARCIA-
SASTRE, A., PALESE, P., WOLFF, K., PEHAMBERGER, H., JAKESZ, R. & 
MUSTER, T. 2001. A genetically engineered influenza A virus with ras-
dependent oncolytic properties. Cancer Res, 61, 8188-93. 
BIFFI, A., MONTINI, E., LORIOLI, L., CESANI, M., FUMAGALLI, F., PLATI, T., 
BALDOLI, C., MARTINO, S., CALABRIA, A., CANALE, S., BENEDICENTI, 
F., VALLANTI, G., BIASCO, L., LEO, S., KABBARA, N., ZANETTI, G., 
RIZZO, W. B., MEHTA, N. A., CICALESE, M. P., CASIRAGHI, M., 
BOELENS, J. J., DEL CARRO, U., DOW, D. J., SCHMIDT, M., ASSANELLI, 
A., NEDUVA, V., DI SERIO, C., STUPKA, E., GARDNER, J., VON KALLE, 
C., BORDIGNON, C., CICERI, F., ROVELLI, A., RONCAROLO, M. G., 
AIUTI, A., SESSA, M. & NALDINI, L. 2013. Lentiviral hematopoietic stem cell 
gene therapy benefits metachromatic leukodystrophy. Science, 341, 1233158. 
BISCHOFF, J. R., KIRN, D. H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., 
NG, L., NYE, J. A., SAMPSON-JOHANNES, A., FATTAEY, A. & 
21 
 
MCCORMICK, F. 1996. An adenovirus mutant that replicates selectively in p53-
deficient human tumor cells. Science, 274, 373-6. 
BOVIATSIS, E. J., PARK, J. S., SENA-ESTEVES, M., KRAMM, C. M., CHASE, M., 
EFIRD, J. T., WEI, M. X., BREAKEFIELD, X. O. & CHIOCCA, E. A. 1994. 
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and 
a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer 
Res, 54, 5745-51. 
BOZTUG, K., SCHMIDT, M., SCHWARZER, A., BANERJEE, P. P., DIEZ, I. A., 
DEWEY, R. A., BOHM, M., NOWROUZI, A., BALL, C. R., GLIMM, H., 
NAUNDORF, S., KUHLCKE, K., BLASCZYK, R., KONDRATENKO, I., 
MARODI, L., ORANGE, J. S., VON KALLE, C. & KLEIN, C. 2010. Stem-cell 
gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med, 363, 1918-27. 
BUCHEIT, A. D., KUMAR, S., GROTE, D. M., LIN, Y., VON MESSLING, V., 
CATTANEO, R. B. & FIELDING, A. K. 2003. An oncolytic measles virus 
engineered to enter cells through the CD20 antigen. Mol Ther, 7, 62-72. 
CARTIER, N. & AUBOURG, P. 2010. Hematopoietic stem cell transplantation and 
hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain 
Pathol, 20, 857-62. 
CARTIER, N., HACEIN-BEY-ABINA, S., BARTHOLOMAE, C. C., VERES, G., 
SCHMIDT, M., KUTSCHERA, I., VIDAUD, M., ABEL, U., DAL-CORTIVO, 
L., CACCAVELLI, L., MAHLAOUI, N., KIERMER, V., MITTELSTAEDT, D., 
BELLESME, C., LAHLOU, N., LEFRERE, F., BLANCHE, S., AUDIT, M., 
PAYEN, E., LEBOULCH, P., L'HOMME, B., BOUGNERES, P., VON KALLE, 
C., FISCHER, A., CAVAZZANA-CALVO, M. & AUBOURG, P. 2009. 
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked 
adrenoleukodystrophy. Science, 326, 818-23. 
CATTANEO, R. 2010. Paramyxovirus entry and targeted vectors for cancer therapy. 
PLoS Pathog, 6, e1000973. 
CATTANEO, R., MIEST, T., SHASHKOVA, E. V. & BARRY, M. A. 2008. 
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat 
Rev Microbiol, 6, 529-40. 
CHALIKONDA, S., KIVLEN, M. H., O'MALLEY, M. E., ERIC DONG, X. D., 
MCCART, J. A., GORRY, M. C., YIN, X. Y., BROWN, C. K., ZEH, H. J., 3RD, 
GUO, Z. S. & BARTLETT, D. L. 2008. Oncolytic virotherapy for ovarian 
carcinomatosis using a replication-selective vaccinia virus armed with a yeast 
cytosine deaminase gene. Cancer Gene Ther, 15, 115-25. 
CHASE, M., CHUNG, R. Y. & CHIOCCA, E. A. 1998. An oncolytic viral mutant that 
delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. 
Nat Biotechnol, 16, 444-8. 
22 
 
CHEN, L., CHEN, D., GONG, M., NA, M., LI, L., WU, H., JIANG, L., QIAN, Y., 
FANG, G. & XUE, X. 2009. Concomitant use of Ad5/35 chimeric oncolytic 
adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in 
gastric cancer cells. Cancer Lett, 284, 141-8. 
CHOU, J., KERN, E. R., WHITLEY, R. J. & ROIZMAN, B. 1990. Mapping of herpes 
simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth 
in culture. Science, 250, 1262-6. 
CINATL, J., JR., MICHAELIS, M., DRIEVER, P. H., CINATL, J., HRABETA, J., 
SUHAN, T., DOERR, H. W. & VOGEL, J. U. 2004. Multimutated herpes 
simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia, 6, 725-35. 
CIRAK, S., ARECHAVALA-GOMEZA, V., GUGLIERI, M., FENG, L., TORELLI, S., 
ANTHONY, K., ABBS, S., GARRALDA, M. E., BOURKE, J., WELLS, D. J., 
DICKSON, G., WOOD, M. J., WILTON, S. D., STRAUB, V., KOLE, R., 
SHREWSBURY, S. B., SEWRY, C., MORGAN, J. E., BUSHBY, K. & 
MUNTONI, F. 2011. Exon skipping and dystrophin restoration in patients with 
Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino 
oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 378, 
595-605. 
CLARKE, J., BUTOWSKI, N. & CHANG, S. 2010. Recent advances in therapy for 
glioblastoma. Arch Neurol, 67, 279-83. 
DIX, B. R., O'CARROLL, S. J., MYERS, C. J., EDWARDS, S. J. & BRAITHWAITE, 
A. W. 2000. Efficient induction of cell death by adenoviruses requires binding of 
E1B55k and p53. Cancer Res, 60, 2666-72. 
DONNELLY, O. G., MELCHER, A. A., VILE, R. G. & PULIDO, J. 2012. What new 
immunotherapeutic techniques are currently being investigated for the treatment 
of melanoma? Immunotherapy, 4, 749-51. 
DOYLE, T. C., BURNS, S. M. & CONTAG, C. H. 2004. In vivo bioluminescence 
imaging for integrated studies of infection. Cell Microbiol, 6, 303-17. 
EGEBLAD, M. & WERB, Z. 2002. New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer, 2, 161-74. 
EVERTS, B. & VAN DER POEL, H. G. 2005. Replication-selective oncolytic viruses in 
the treatment of cancer. Cancer Gene Ther, 12, 141-61. 
FERGUSON, M. S., LEMOINE, N. R. & WANG, Y. 2012. Systemic delivery of 
oncolytic viruses: hopes and hurdles. Adv Virol, 2012, 805629. 
FLOTTE, T., CARTER, B., CONRAD, C., GUGGINO, W., REYNOLDS, T., 
ROSENSTEIN, B., TAYLOR, G., WALDEN, S. & WETZEL, R. 1996. A phase I 
23 
 
study of an adeno-associated virus-CFTR gene vector in adult CF patients with 
mild lung disease. Hum Gene Ther, 7, 1145-59. 
FOLOPPE, J., KINTZ, J., FUTIN, N., FINDELI, A., CORDIER, P., SCHLESINGER, 
Y., HOFFMANN, C., TOSCH, C., BALLOUL, J. M. & ERBS, P. 2008. Targeted 
delivery of a suicide gene to human colorectal tumors by a conditionally 
replicating vaccinia virus. Gene Ther, 15, 1361-71. 
FOX, N. L., HUMPHREYS, R., LUSTER, T. A., KLEIN, J. & GALLANT, G. 2010. 
Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 
and Receptor-2 agonists for cancer therapy. Expert Opin Biol Ther, 10, 1-18. 
FRIEDRICH, I., SHIR, A., KLEIN, S. & LEVITZKI, A. 2004. RNA molecules as anti-
cancer agents. Semin Cancer Biol, 14, 223-30. 
FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P. S., MCDONNELL, T. 
J., MITLIANGA, P., SHI, Y. X., LEVIN, V. A., YUNG, W. K. & KYRITSIS, A. 
P. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-
glioma effect in vivo. Oncogene, 19, 2-12. 
GIANNI, T., CAMPADELLI-FIUME, G. & MENOTTI, L. 2004. Entry of herpes 
simplex virus mediated by chimeric forms of nectin1 retargeted to endosomes or 
to lipid rafts occurs through acidic endosomes. J Virol, 78, 12268-76. 
GOMEZ, C. E., NAJERA, J. L., KRUPA, M. & ESTEBAN, M. 2008. The poxvirus 
vectors MVA and NYVAC as gene delivery systems for vaccination against 
infectious diseases and cancer. Curr Gene Ther, 8, 97-120. 
GOVERDHANA, S., PUNTEL, M., XIONG, W., ZIRGER, J. M., BARCIA, C., 
CURTIN, J. F., SOFFER, E. B., MONDKAR, S., KING, G. D., HU, J., 
SCIASCIA, S. A., CANDOLFI, M., GREENGOLD, D. S., LOWENSTEIN, P. R. 
& CASTRO, M. G. 2005. Regulatable gene expression systems for gene therapy 
applications: progress and future challenges. Mol Ther, 12, 189-211. 
GREEN, N. K. & SEYMOUR, L. W. 2002. Adenoviral vectors: systemic delivery and 
tumor targeting. Cancer Gene Ther, 9, 1036-42. 
GRIMM, S. & NOTEBORN, M. 2010. Anticancer genes: inducers of tumour-specific 
cell death signalling. Trends Mol Med, 16, 88-96. 
GUO, Z. S. & BARTLETT, D. L. 2004. Vaccinia as a vector for gene delivery. Expert 
Opin Biol Ther, 4, 901-17. 
GUO, Z. S., THORNE, S. H. & BARTLETT, D. L. 2008. Oncolytic virotherapy: 
molecular targets in tumor-selective replication and carrier cell-mediated delivery 
of oncolytic viruses. Biochim Biophys Acta, 1785, 217-31. 
24 
 
HALLGREN, O., AITS, S., BREST, P., GUSTAFSSON, L., MOSSBERG, A. K., 
WULLT, B. & SVANBORG, C. 2008. Apoptosis and tumor cell death in 
response to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Adv 
Exp Med Biol, 606, 217-40. 
HAMADA, K., DESAKI, J., NAKAGAWA, K., ZHANG, T., SHIRAKAWA, T., 
GOTOH, A. & TAGAWA, M. 2007. Carrier cell-mediated delivery of a 
replication-competent adenovirus for cancer gene therapy. Mol Ther, 15, 1121-8. 
HANAHAN, D. & WEINBERG, R. A. 2011. Hallmarks of cancer: the next generation. 
Cell, 144, 646-74. 
HARADA, J. N. & BERK, A. J. 1999. p53-Independent and -dependent requirements for 
E1B-55K in adenovirus type 5 replication. J Virol, 73, 5333-44. 
HARDCASTLE, J., KUROZUMI, K., CHIOCCA, E. A. & KAUR, B. 2007. Oncolytic 
viruses driven by tumor-specific promoters. Curr Cancer Drug Targets, 7, 181-9. 
HEISE, C., HERMISTON, T., JOHNSON, L., BROOKS, G., SAMPSON-JOHANNES, 
A., WILLIAMS, A., HAWKINS, L. & KIRN, D. 2000. An adenovirus E1A 
mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat 
Med, 6, 1134-9. 
HOSTER, H. A., ZANES, R. P., JR. & VON HAAM, E. 1949. Studies in Hodgkin's 
syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary 
report. Cancer Res, 9, 473-80. 
HUANG, T. G., SAVONTAUS, M. J., SHINOZAKI, K., SAUTER, B. V. & WOO, S. L. 
2003. Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene 
Ther, 10, 1241-7. 
IGUCHI, K., SAKURAI, F., TOMITA, K., KATAYAMA, K., YAMAGUCHI, T., 
KAWABATA, K., TAGAWA, M., KAWABATA, M., SHIRAKAWA, T. & 
MIZUGUCHI, H. 2012. Efficient antitumor effects of carrier cells loaded with a 
fiber-substituted conditionally replicating adenovirus on CAR-negative tumor 
cells. Cancer Gene Ther, 19, 118-25. 
INOUE, S., SHANKER, M., MIYAHARA, R., GOPALAN, B., PATEL, S., OIDA, Y., 
BRANCH, C. D., MUNSHI, A., MEYN, R. E., ANDREEFF, M., TANAKA, F., 
MHASHILKAR, A. M., CHADA, S. & RAMESH, R. 2006. MDA-7/IL-24-based 
cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther, 
6, 73-91. 
JIN, J., LIU, H., YANG, C., LI, G., LIU, X., QIAN, Q. & QIAN, W. 2009. Effective 
gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus 
expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther, 8, 1387-97. 
25 
 
JONES, S., ZHANG, X., PARSONS, D. W., LIN, J. C., LEARY, R. J., ANGENENDT, 
P., MANKOO, P., CARTER, H., KAMIYAMA, H., JIMENO, A., HONG, S. M., 
FU, B., LIN, M. T., CALHOUN, E. S., KAMIYAMA, M., WALTER, K., 
NIKOLSKAYA, T., NIKOLSKY, Y., HARTIGAN, J., SMITH, D. R., 
HIDALGO, M., LEACH, S. D., KLEIN, A. P., JAFFEE, E. M., GOGGINS, M., 
MAITRA, A., IACOBUZIO-DONAHUE, C., ESHLEMAN, J. R., KERN, S. E., 
HRUBAN, R. H., KARCHIN, R., PAPADOPOULOS, N., PARMIGIANI, G., 
VOGELSTEIN, B., VELCULESCU, V. E. & KINZLER, K. W. 2008. Core 
signaling pathways in human pancreatic cancers revealed by global genomic 
analyses. Science, 321, 1801-6. 
KAUR, B., CRIPE, T. P. & CHIOCCA, E. A. 2009. "Buy one get one free": armed 
viruses for the treatment of cancer cells and their microenvironment. Curr Gene 
Ther, 9, 341-55. 
KAY, M. A., MANNO, C. S., RAGNI, M. V., LARSON, P. J., COUTO, L. B., 
MCCLELLAND, A., GLADER, B., CHEW, A. J., TAI, S. J., HERZOG, R. W., 
ARRUDA, V., JOHNSON, F., SCALLAN, C., SKARSGARD, E., FLAKE, A. 
W. & HIGH, K. A. 2000. Evidence for gene transfer and expression of factor IX 
in haemophilia B patients treated with an AAV vector. Nat Genet, 24, 257-61. 
KELLY, E. & RUSSELL, S. J. 2007. History of oncolytic viruses: genesis to genetic 
engineering. Mol Ther, 15, 651-9. 
KINALI, M., ARECHAVALA-GOMEZA, V., FENG, L., CIRAK, S., HUNT, D., 
ADKIN, C., GUGLIERI, M., ASHTON, E., ABBS, S., NIHOYANNOPOULOS, 
P., GARRALDA, M. E., RUTHERFORD, M., MCCULLEY, C., POPPLEWELL, 
L., GRAHAM, I. R., DICKSON, G., WOOD, M. J., WELLS, D. J., WILTON, S. 
D., KOLE, R., STRAUB, V., BUSHBY, K., SEWRY, C., MORGAN, J. E. & 
MUNTONI, F. 2009. Local restoration of dystrophin expression with the 
morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, 
placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol, 8, 
918-28. 
KLENK, H. D. & GARTEN, W. 1994. Host cell proteases controlling virus 
pathogenicity. Trends Microbiol, 2, 39-43. 
KOEHLER, D. R., FRNDOVA, H., LEUNG, K., LOUCA, E., PALMER, D., NG, P., 
MCKERLIE, C., COX, P., COATES, A. L. & HU, J. 2005. Aerosol delivery of an 
enhanced helper-dependent adenovirus formulation to rabbit lung using an 
intratracheal catheter. J Gene Med, 7, 1409-20. 
KOEHLER, D. R., MARTIN, B., COREY, M., PALMER, D., NG, P., TANSWELL, A. 
K. & HU, J. 2006. Readministration of helper-dependent adenovirus to mouse 
lung. Gene Ther, 13, 773-80. 
26 
 
KUMAR, S., GAO, L., YEAGY, B. & REID, T. 2008. Virus combinations and 
chemotherapy for the treatment of human cancers. Curr Opin Mol Ther, 10, 371-
9. 
KURODA, T., RABKIN, S. D. & MARTUZA, R. L. 2006. Effective treatment of tumors 
with strong beta-catenin/T-cell factor activity by transcriptionally targeted 
oncolytic herpes simplex virus vector. Cancer Res, 66, 10127-35. 
LAI, C. M., LAI, Y. K. & RAKOCZY, P. E. 2002. Adenovirus and adeno-associated 
virus vectors. DNA Cell Biol, 21, 895-913. 
LAMFERS, M. L., GIANNI, D., TUNG, C. H., IDEMA, S., SCHAGEN, F. H., 
CARETTE, J. E., QUAX, P. H., VAN BEUSECHEM, V. W., VANDERTOP, W. 
P., DIRVEN, C. M., CHIOCCA, E. A. & GERRITSEN, W. R. 2005. Tissue 
inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits 
matrix metalloproteinase activity in vivo without affecting antitumor efficacy in 
malignant glioma. Cancer Res, 65, 9398-405. 
LEWITT, P. A., REZAI, A. R., LEEHEY, M. A., OJEMANN, S. G., FLAHERTY, A. 
W., ESKANDAR, E. N., KOSTYK, S. K., THOMAS, K., SARKAR, A., 
SIDDIQUI, M. S., TATTER, S. B., SCHWALB, J. M., POSTON, K. L., 
HENDERSON, J. M., KURLAN, R. M., RICHARD, I. H., VAN METER, L., 
SAPAN, C. V., DURING, M. J., KAPLITT, M. G. & FEIGIN, A. 2011. AAV2-
GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-
surgery controlled, randomised trial. Lancet Neurol, 10, 309-19. 
LORENCE, R. M., ROOD, P. A. & KELLEY, K. W. 1988. Newcastle disease virus as an 
antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation 
of its cytotoxicity. J Natl Cancer Inst, 80, 1305-12. 
MAHLLER, Y. Y., VAIKUNTH, S. S., RIPBERGER, M. C., BAIRD, W. H., SAEKI, 
Y., CANCELAS, J. A., CROMBLEHOLME, T. M. & CRIPE, T. P. 2008. Tissue 
inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth 
and vascular progenitors. Cancer Res, 68, 1170-9. 
MARKERT, J. M., MEDLOCK, M. D., RABKIN, S. D., GILLESPIE, G. Y., TODO, T., 
HUNTER, W. D., PALMER, C. A., FEIGENBAUM, F., TORNATORE, C., 
TUFARO, F. & MARTUZA, R. L. 2000. Conditionally replicating herpes 
simplex virus mutant, G207 for the treatment of malignant glioma: results of a 
phase I trial. Gene Ther, 7, 867-74. 
MEIER, O. & GREBER, U. F. 2003. Adenovirus endocytosis. J Gene Med, 5, 451-62. 
MEIROW, D. & NUGENT, D. 2001. The effects of radiotherapy and chemotherapy on 
female reproduction. Hum Reprod Update, 7, 535-43. 
27 
 
MINETA, T., RABKIN, S. D., YAZAKI, T., HUNTER, W. D. & MARTUZA, R. L. 
1995. Attenuated multi-mutated herpes simplex virus-1 for the treatment of 
malignant gliomas. Nat Med, 1, 938-43. 
MORLING, F. J., PENG, K. W., COSSET, F. L. & RUSSELL, S. J. 1997. Masking of 
retroviral envelope functions by oligomerizing polypeptide adaptors. Virology, 
234, 51-61. 
MOROZIEWICZ, D. & KAUFMAN, H. L. 2005. Gene therapy with poxvirus vectors. 
Curr Opin Mol Ther, 7, 317-25. 
MOSS, B. 1996. Genetically engineered poxviruses for recombinant gene expression, 
vaccination, and safety. Proc Natl Acad Sci U S A, 93, 11341-8. 
MSAOUEL, P., DISPENZIERI, A. & GALANIS, E. 2009. Clinical testing of engineered 
oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin 
Mol Ther, 11, 43-53. 
MSAOUEL, P., OPYRCHAL, M., DOMINGO MUSIBAY, E. & GALANIS, E. 2013. 
Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther, 
13, 483-502. 
MUSTER, T., RAJTAROVA, J., SACHET, M., UNGER, H., FLEISCHHACKER, R., 
ROMIRER, I., GRASSAUER, A., URL, A., GARCIA-SASTRE, A., WOLFF, 
K., PEHAMBERGER, H. & BERGMANN, M. 2004. Interferon resistance 
promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer, 110, 
15-21. 
NAGANO, S., OSHIKA, H., FUJIWARA, H., KOMIYA, S. & KOSAI, K. 2005. An 
efficient construction of conditionally replicating adenoviruses that target tumor 
cells with multiple factors. Gene Ther, 12, 1385-93. 
NAKANO, K., ASANO, R., TSUMOTO, K., KWON, H., GOINS, W. F., KUMAGAI, 
I., COHEN, J. B. & GLORIOSO, J. C. 2005. Herpes simplex virus targeting to 
the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther, 11, 617-
26. 
NATARAJAN, N., TELANG, S., MILLER, D. & CHESNEY, J. 2011. Novel 
immunotherapeutic agents and small molecule antagonists of signalling kinases 
for the treatment of metastatic melanoma. Drugs, 71, 1233-50. 
NAYEROSSADAT, N., MAEDEH, T. & ALI, P. A. 2012. Viral and nonviral delivery 
systems for gene delivery. Adv Biomed Res, 1, 27. 
NOSER, J. A., MAEL, A. A., SAKUMA, R., OHMINE, S., MARCATO, P., LEE, P. W. 
& IKEDA, Y. 2007. The RAS/Raf1/MEK/ERK signaling pathway facilitates 
VSV-mediated oncolysis: implication for the defective interferon response in 
cancer cells. Mol Ther, 15, 1531-6. 
28 
 
O'SHEA, C. C., JOHNSON, L., BAGUS, B., CHOI, S., NICHOLAS, C., SHEN, A., 
BOYLE, L., PANDEY, K., SORIA, C., KUNICH, J., SHEN, Y., HABETS, G., 
GINZINGER, D. & MCCORMICK, F. 2004. Late viral RNA export, rather than 
p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell, 6, 611-
23. 
PAL, S. K., FIGLIN, R. A. & RECKAMP, K. 2010. Targeted therapies for non-small cell 
lung cancer: an evolving landscape. Mol Cancer Ther, 9, 1931-44. 
PALFI, S., GURRUCHAGA, J.M.,, RALPH, S.G., LEPETIT, H., LAVISSE, S., 
BUTTERY, P. C., WATTS C., MISKIN, J., KELLEHER, M., DEELEY, S., 
IWAMURO, H, LEFAUCHEUR, J. P., THIRIEZ, C., FENELON, G., LUCAS, 
C., BRUGIÈRES, P., GABRIEL, I., ABHAY, K., DROUOT, X., TANI, N., KAS, 
A., GHALEH, B., CORVOISIER, P.L., DOLPHIN, P., BREEN, D. P., MASON, 
S., GUZMAN, N. V., MAZARAKIS N.D., RADCLIFFE P.A., HARROP R., 
KINGSMAN, S.M., RASCO,L O., NAYLOR S., BARKER, R. A., HANTRAYE, 
P., REMY, P., CESARO, P., MITROPHANOUS K.A.2013. Long-term safety 
and tolerability of ProSavin, a lentiviral vector-based gene therapy for 
Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial Lancet, 382  
PASSINI, M. A., BU, J., RICHARDS, A. M., KINNECOM, C., SARDI, S. P., STANEK, 
L. M., HUA, Y., RIGO, F., MATSON, J., HUNG, G., KAYE, E. M., 
SHIHABUDDIN, L. S., KRAINER, A. R., BENNETT, C. F. & CHENG, S. H. 
2011. Antisense oligonucleotides delivered to the mouse CNS ameliorate 
symptoms of severe spinal muscular atrophy. Sci Transl Med, 3, 72ra18. 
PENG, K. W., DONOVAN, K. A., SCHNEIDER, U., CATTANEO, R., LUST, J. A. & 
RUSSELL, S. J. 2003. Oncolytic measles viruses displaying a single-chain 
antibody against CD38, a myeloma cell marker. Blood, 101, 2557-62. 
PENG, K. W., HADAC, E. M., ANDERSON, B. D., MYERS, R., HARVEY, M., 
GREINER, S. M., SOEFFKER, D., FEDERSPIEL, M. J. & RUSSELL, S. J. 
2006. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium 
between virus and tumor in an ovarian cancer xenograft model. Cancer Gene 
Ther, 13, 732-8. 
PENG, K. W., VILE, R., COSSET, F. L. & RUSSELL, S. 1999. Selective transduction of 
protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. 
Gene Ther, 6, 1552-7. 
PENG, Z. 2005. Current status of gendicine in China: recombinant human Ad-p53 agent 
for treatment of cancers. Hum Gene Ther, 16, 1016-27. 
PIWNICA-WORMS, D., SCHUSTER, D. P. & GARBOW, J. R. 2004. Molecular 
imaging of host-pathogen interactions in intact small animals. Cell Microbiol, 6, 
319-31. 
29 
 
REICHARD, K. W., LORENCE, R. M., CASCINO, C. J., PEEPLES, M. E., WALTER, 
R. J., FERNANDO, M. B., REYES, H. M. & GREAGER, J. A. 1992. Newcastle 
disease virus selectively kills human tumor cells. J Surg Res, 52, 448-53. 
SASAKI, T., RODIG, S. J., CHIRIEAC, L. R. & JANNE, P. A. 2010. The biology and 
treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer, 46, 1773-80. 
SAUANE, M., SU, Z. Z., GUPTA, P., LEBEDEVA, I. V., DENT, P., SARKAR, D. & 
FISHER, P. B. 2008. Autocrine regulation of mda-7/IL-24 mediates cancer-
specific apoptosis. Proc Natl Acad Sci U S A, 105, 9763-8. 
SCHLIEMANN, C. & NERI, D. 2007. Antibody-based targeting of the tumor 
vasculature. Biochim Biophys Acta, 1776, 175-92. 
SHERR, C. J. 1996. Cancer cell cycles. Science, 274, 1672-7. 
SIMONELLI, F., MAGUIRE, A. M., TESTA, F., PIERCE, E. A., MINGOZZI, F., 
BENNICELLI, J. L., ROSSI, S., MARSHALL, K., BANFI, S., SURACE, E. M., 
SUN, J., REDMOND, T. M., ZHU, X., SHINDLER, K. S., YING, G. S., 
ZIVIELLO, C., ACERRA, C., WRIGHT, J. F., MCDONNELL, J. W., HIGH, K. 
A., BENNETT, J. & AURICCHIO, A. 2010. Gene therapy for Leber's congenital 
amaurosis is safe and effective through 1.5 years after vector administration. Mol 
Ther, 18, 643-50. 
SINKOVICS, J. & HORVATH, J. 1993. New developments in the virus therapy of 
cancer: a historical review. Intervirology, 36, 193-214. 
SMITH, K. D., MEZHIR, J. J., BICKENBACH, K., VEERAPONG, J., CHARRON, J., 
POSNER, M. C., ROIZMAN, B. & WEICHSELBAUM, R. R. 2006. Activated 
MEK suppresses activation of PKR and enables efficient replication and in vivo 
oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol, 80, 
1110-20. 
SPEAR, P. G. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell 
Microbiol, 6, 401-10. 
SPRINGFELD, C., VON MESSLING, V., FRENZKE, M., UNGERECHTS, G., 
BUCHHOLZ, C. J. & CATTANEO, R. 2006. Oncolytic efficacy and enhanced 
safety of measles virus activated by tumor-secreted matrix metalloproteinases. 
Cancer Res, 66, 7694-700. 
SPURBECK, W. W., NG, C. Y., VANIN, E. F. & DAVIDOFF, A. M. 2003. Retroviral 
vector-producer cell-mediated in vivo gene transfer of TIMP-3 restricts 
angiogenesis and neuroblastoma growth in mice. Cancer Gene Ther, 10, 161-7. 
STOFF-KHALILI, M. A., RIVERA, A. A., MATHIS, J. M., BANERJEE, N. S., MOON, 
A. S., HESS, A., ROCCONI, R. P., NUMNUM, T. M., EVERTS, M., CHOW, L. 
T., DOUGLAS, J. T., SIEGAL, G. P., ZHU, Z. B., BENDER, H. G., DALL, P., 
30 
 
STOFF, A., PEREBOEVA, L. & CURIEL, D. T. 2007. Mesenchymal stem cells 
as a vehicle for targeted delivery of CRAds to lung metastases of breast 
carcinoma. Breast Cancer Res Treat, 105, 157-67. 
STOJDL, D. F., LICHTY, B. D., TENOEVER, B. R., PATERSON, J. M., POWER, A. 
T., KNOWLES, S., MARIUS, R., REYNARD, J., POLIQUIN, L., ATKINS, H., 
BROWN, E. G., DURBIN, R. K., DURBIN, J. E., HISCOTT, J. & BELL, J. C. 
2003. VSV strains with defects in their ability to shutdown innate immunity are 
potent systemic anti-cancer agents. Cancer Cell, 4, 263-75. 
STRIPECKE, R., KOYA, R. C., TA, H. Q., KASAHARA, N. & LEVINE, A. M. 2003. 
The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene 
delivery of immunomodulators into leukemia cells by state-of-the-art vectors. 
Blood Cells Mol Dis, 31, 28-37. 
SUZUKI, S., NAKASATO, M., SHIBUE, T., KOSHIMA, I. & TANIGUCHI, T. 2009. 
Therapeutic potential of proapoptotic molecule Noxa in the selective elimination 
of tumor cells. Cancer Sci, 100, 759-69. 
THOMAS, C. E., EHRHARDT, A. & KAY, M. A. 2003. Progress and problems with the 
use of viral vectors for gene therapy. Nat Rev Genet, 4, 346-58. 
TODO, T. 2008a. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. 
Cell Adh Migr, 2, 208-13. 
TODO, T. 2008b. Oncolytic virus therapy using genetically engineered herpes simplex 
viruses. Front Biosci, 13, 2060-4. 
TODO, T., MARTUZA, R. L., RABKIN, S. D. & JOHNSON, P. A. 2001. Oncolytic 
herpes simplex virus vector with enhanced MHC class I presentation and tumor 
cell killing. Proc Natl Acad Sci U S A, 98, 6396-401. 
TONG, A. W., NEMUNAITIS, J., SU, D., ZHANG, Y., CUNNINGHAM, C., SENZER, 
N., NETTO, G., RICH, D., MHASHILKAR, A., PARKER, K., COFFEE, K., 
RAMESH, R., EKMEKCIOGLU, S., GRIMM, E. A., VAN WART HOOD, J., 
MERRITT, J. & CHADA, S. 2005. Intratumoral injection of INGN 241, a 
nonreplicating adenovector expressing the melanoma-differentiation associated 
gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther, 
11, 160-72. 
TROBRIDGE, G. D. 2009. Foamy virus vectors for gene transfer. Expert Opin Biol Ther, 
9, 1427-36. 
VAN DEUTEKOM, J. C., JANSON, A. A., GINJAAR, I. B., FRANKHUIZEN, W. S., 
AARTSMA-RUS, A., BREMMER-BOUT, M., DEN DUNNEN, J. T., KOOP, 
K., VAN DER KOOI, A. J., GOEMANS, N. M., DE KIMPE, S. J., EKHART, P. 
F., VENNEKER, E. H., PLATENBURG, G. J., VERSCHUUREN, J. J. & VAN 
31 
 
OMMEN, G. J. 2007. Local dystrophin restoration with antisense oligonucleotide 
PRO051. N Engl J Med, 357, 2677-86. 
VEERAPONG, J., BICKENBACH, K. A., SHAO, M. Y., SMITH, K. D., POSNER, M. 
C., ROIZMAN, B. & WEICHSELBAUM, R. R. 2007. Systemic delivery of 
(gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant 
human xenograft tumors that express high MEK activity. Cancer Res, 67, 8301-6. 
VOGELSTEIN, B. & KINZLER, K. W. 2004. Cancer genes and the pathways they 
control. Nat Med, 10, 789-99. 
VORBURGER, S. A. & HUNT, K. K. 2002. Adenoviral gene therapy. Oncologist, 7, 46-
59. 
WAEHLER, R., RUSSELL, S. J. & CURIEL, D. T. 2007. Engineering targeted viral 
vectors for gene therapy. Nat Rev Genet, 8, 573-87. 
WANG, X., SU, C., CAO, H., LI, K., CHEN, J., JIANG, L., ZHANG, Q., WU, X., JIA, 
X., LIU, Y., WANG, W., LIU, X., WU, M. & QIAN, Q. 2008. A novel triple-
regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy 
on common human solid cancers. Mol Cancer Ther, 7, 1598-603. 
WINKELER, A., SENA-ESTEVES, M., PAULIS, L. E., LI, H., WAERZEGGERS, Y., 
RUCKRIEM, B., HIMMELREICH, U., KLEIN, M., MONFARED, P., 
RUEGER, M. A., HENEKA, M., VOLLMAR, S., HOEHN, M., FRAEFEL, C., 
GRAF, R., WIENHARD, K., HEISS, W. D. & JACOBS, A. H. 2007. Switching 
on the lights for gene therapy. PLoS One, 2, e528. 
WONG, H. H., LEMOINE, N. R. & WANG, Y. 2010. Oncolytic Viruses for Cancer 
Therapy: Overcoming the Obstacles. Viruses, 2, 78-106. 
WU, Q., MOYANA, T. & XIANG, J. 2001. Cancer gene therapy by adenovirus-mediated 
gene transfer. Curr Gene Ther, 1, 101-22. 
YI, Y., NOH, M. J. & LEE, K. H. 2011. Current advances in retroviral gene therapy. 
Curr Gene Ther, 11, 218-28. 
YUAN, L., ZHAO, H., ZHANG, L. & LIU, X. 2013. The efficacy of combination 
therapy using adeno-associated virus-mediated co-expression of apoptin and 
interleukin-24 on hepatocellular carcinoma. Tumour Biol, 34, 3027-34. 
ZHANG, K. X., MOUSSAVI, M., KIM, C., CHOW, E., CHEN, I. S., FAZLI, L., JIA, 
W. & RENNIE, P. S. 2009a. Lentiviruses with trastuzumab bound to their 
envelopes can target and kill prostate cancer cells. Cancer Gene Ther, 16, 820-31. 
ZHANG, Z., HUANG, Y., NEWMAN, K., GU, J., ZHANG, X., WU, H., ZHAO, M., 
XIANYU, Z. & LIU, X. 2009b. Reexpression of human somatostatin receptor 
gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of 
32 
 
tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer. 
Clin Cancer Res, 15, 5154-60. 
 
 
